Display options
Cite
Chernomordik F, Freimark D, Arad M, et al. Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting. ESC Heart Fail. 2016;4(2):122-129doi: 10.1002/ehf2.12114.
Chernomordik, F., Freimark, D., Arad, M., Shechter, M., Matetzky, S., Savir, Y., Shlomo, N., Peled, A., Goldenberg, I., & Peled, Y. (2017). Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting. ESC heart failure, 4(2), 122-129. https://doi.org/10.1002/ehf2.12114
Chernomordik, Fernando, et al. "Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting." ESC heart failure vol. 4,2 (2017): 122-129. doi: https://doi.org/10.1002/ehf2.12114
Chernomordik F, Freimark D, Arad M, Shechter M, Matetzky S, Savir Y, Shlomo N, Peled A, Goldenberg I, Peled Y. Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting. ESC Heart Fail. 2017 May;4(2):122-129. doi: 10.1002/ehf2.12114. Epub 2016 Sep 17. PMID: 28451448; PMCID: PMC5396040.
Copy Download .nbib Format: NLM
Share it on

ESC Heart Fail. 2017 May;4(2):122-129. doi: 10.1002/ehf2.12114. Epub 2016 Sep 17.

Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting.

ESC heart failure

Fernando Chernomordik, Dov Freimark, Michael Arad, Michael Shechter, Shlomi Matetzky, Yulia Savir, Nir Shlomo, Amir Peled, Ilan Goldenberg, Yael Peled

Affiliations

  1. Heart Failure Institute, Heart Centre, Sheba Medical Centre and Sackler School of MedicineTel Aviv UniversityTel AvivIsrael.
  2. The Israeli Association for Cardiovascular TrialsTel HashomerIsrael.
  3. Clalit Health ServicesCentral RegionIsrael.

PMID: 28451448 PMCID: PMC5396040 DOI: 10.1002/ehf2.12114

Abstract

AIMS: There are limited data on the effect of low-dose, intermittent inotropic therapy in an outpatient setting on the quality of life (QOL) in patients with advanced refractory heart failure (HF) symptoms. We aimed to analyse the effect of this treatment modality on QOL and subsequent survival.

METHODS AND RESULTS: The study population comprised 287 consecutive patients with advanced refractory HF symptoms who were treated with low-dose, intravenous intermittent inotropic therapy in the HF Day Care Service at Sheba Medical Centre between September 2000 and September 2012. All patients completed a baseline Minnesota Living with Heart Failure Questionnaire (MLWHFQ), and 137 (48%) completed a 1 year follow-up questionnaire. MLWHFQ scores' means ranged from 0 (better QOL) to 5 (worse QOL). Mean age was 68 ± 12, 86% were men, 77% had ischaemic cardiomyopathy, and the mean left ventricle ejection fraction (LVEF) was 26% ± 13. The mean baseline MLWHFQ score was 3.1 (±1), while the mean at 1 year of treatment was of 2.7 (±1.1), indicating an overall improvement in QOL associated with intermittent low-dose inotrope therapy (

CONCLUSIONS: In patients with advanced refractory HF symptoms, treatment with low-dose, intermittent intravenous inotropes in an outpatient setting is associated with significant improvement in QOL. However, improvement in QOL in this population does not appear to affect subsequent long-term survival.

Keywords: Heart failure; Intermittent inotropes; Quality of life; Survival

References

  1. Heart. 1996 Sep;76(3):223-31 - PubMed
  2. J Am Coll Cardiol. 1984 May;3(5):1282-90 - PubMed
  3. Int J Gen Med. 2014 May 20;7:237-51 - PubMed
  4. Isr Med Assoc J. 2009 Jul;11(7):419-25 - PubMed
  5. Am Heart J. 1980 Nov;100(5):622-30 - PubMed
  6. Clin Pharm. 1985 Mar-Apr;4(2):195-9 - PubMed
  7. Am J Cardiol. 1993 May 1;71(12):1069-73 - PubMed
  8. Heart. 2007 Sep;93(9):1137-46 - PubMed
  9. J Am Coll Cardiol. 2003 May 7;41(9):1510-8 - PubMed
  10. Am Heart J. 1998 Jan;135(1):121-9 - PubMed
  11. Am Heart J. 1992 Oct;124(4):1017-25 - PubMed
  12. Qual Life Res. 2002 Jun;11(4):349-59 - PubMed
  13. Eur Heart J. 2012 Jul;33(14):1787-847 - PubMed
  14. Clin Cardiol. 2004 Jan;27(1):23-8 - PubMed
  15. Am J Cardiol. 1987 Aug 14;60(5):75C-79C - PubMed
  16. N Engl J Med. 2001 Nov 15;345(20):1435-43 - PubMed
  17. N Engl J Med. 1998 Dec 17;339(25):1810-6 - PubMed
  18. Lancet. 1990 Jul 7;336(8706):1-6 - PubMed
  19. Eur Heart J. 2009 Dec;30(24):3015-26 - PubMed
  20. Circulation. 1990 Sep;82(3):774-80 - PubMed
  21. J Med. 2002;33(1-4):129-46 - PubMed
  22. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):684-94 - PubMed
  23. N Engl J Med. 1993 Jul 15;329(3):149-55 - PubMed
  24. N Engl J Med. 1991 Nov 21;325(21):1468-75 - PubMed
  25. Am Heart J. 1986 Oct;112(4):787-91 - PubMed
  26. ESC Heart Fail. 2017 May;4(2):122-129 - PubMed
  27. Eur J Heart Fail. 2014 Aug;16(8):898-906 - PubMed
  28. Int J Cardiol. 1990 Jul;28 Suppl 1:S33-42; discussion S43 - PubMed
  29. Intensive Care Med. 2011 Apr;37(4):619-26 - PubMed
  30. Pharmacol Rev. 1972 Mar;24(1):1-29 - PubMed
  31. J Am Coll Cardiol. 2014 May 27;63(20):2069-2078 - PubMed
  32. N Engl J Med. 2006 Jul 20;355(3):251-9 - PubMed
  33. Lancet. 1997 Apr 5;349(9057):971-7 - PubMed

Publication Types